Investigating New Cancer Treatment Options
to Improve Patients’ Lives


Immune Design is developing first-in-class immuno-oncology drug candidates designed to make a meaningful difference for cancer patients. We are working with Genentech and Merck as clinical collaborators in two randomized Phase 2 trials to study the potential benefit for patients of combining our lead product candidates – CMB305 and G100 – which each embody distinct approaches to fighting cancer, with checkpoint inhibitors. Below, please find a list of our current clinical trials.


Title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Objective: Evaluate the safety and clinical efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone in patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma expressing the NY-ESO-1 cancer testis antigen.

Status: Recruiting

More Information: identifier: NCT02609984.

NY-ESO-1 Expressing Cancers: CMB305

Title: A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Objective: Evaluate the safety and tolerability, immunogenicity, and preliminary clinical efficacy of CMB305 in patients with locally advanced, relapsed or metastatic solid cancers, whose tumors express NY-ESO-1.

Status: Recruiting

More Information: identifier: NCT0237125

Follicular Non-Hodgkin’s Lymphoma: G100

Title: Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma

Objective: To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular non-Hodgkin’s lymphoma (NHL) receiving local radiation

Status: Recruiting

More Information: identifier: NCT02501473